The FullCYTE® Breast Aspirator is now available!

Click here.

Atossa Genetics is a healthcare company developing proprietary laboratory services, medical devices, and therapeutics in breast health and breast care. Our products are designed to provide critical information that empowers women and their healthcare providers to take charge of and protect their breast health today and in the future.

Our laboratory services are offered through our wholly owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH).

Atossa In the News

Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update

Atossa Genetics to Announce Third Quarter 2015 Financial results and Provide a Company Update on Thursday, November 12, 2015

Atossa Genetics hires Janet Rose Rea, M.S.P.H. as VP Regulatory Affairs and Quality

Atossa Genetics to Present at Upcoming Investor Conferences

Atossa Genetics’ Laboratory Receives ISO 15189:2012 Certification

Atossa Genetics Announces FDA Acceptance of its Investigational New Drug Application to Begin a Phase II Clinical Trial of Fulvestrant for the Treatment of DCIS

Atossa Genetics Receives Approval to Begin Clinical Study in Israel

Atossa Genetics, Inc. to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

Atossa Genetics, Inc. Announces Appointment of Scott Youmans as Chief Operating Officer

Atossa Genetics Announces Second Quarter 2015 Financial Results and Provides Company Update; Achieves Total Revenue for Q2 of $2.7 Million

Atossa Genetics to Announce Second Quarter 2015 Financial Results and Provide a Company Update on Thursday, August 6, 2015

Atossa Genetics and AAIPharma / Cambridge Major Laboratories Announce Manufacturing Agreement for Atossa’s Lead Drug Candidate Afimoxifene Gel

Atossa Genetics Subsidiary the NRLBH Now Provides Enhanced Pharmacogenetic Test Based on Luminex xTAG Platform

Atossa Genetics Announces Acquisition of Ductal Lavage Specimen Bank From the Dr. Susan Love Research Foundation

Atossa Genetics Announces Issuance of Patent US9,052,318 by the U.S. Patent and Trademark for Breast Cancer Detection Using Absorbent Paper

Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors

Atossa Genetics to Present at the LD Micro Invitational Conference on Tuesday, June 2, 2015

Atossa Genetics Hires Dr. Gerald Engley as Senior Director of Medical Affairs

Atossa Genetics to Host Conference Call Today, Monday, May 18, 2015 at 4:30pm Eastern Time to Provide Company Update

Atossa Genetics Acquires Rights to Clinical Stage Proprietary Afimoxifene Gel for Potential Treatment of Hyperplasia of the Breast

More Press Releases Go